RT Journal Article
SR Electronic
T1 Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.23.21257679
DO 10.1101/2021.05.23.21257679
A1 McEwen, Abbye E.
A1 Cohen, Seth
A1 Bryson-Cahn, Chloe
A1 Liu, Catherine
A1 Pergam, Steven A.
A1 Lynch, John
A1 Schippers, Adrienne
A1 Strand, Kathy
A1 Whimbey, Estella
A1 Mani, Nandita S
A1 Zelikoff, Allison J.
A1 Makarewicz, Vanessa A.
A1 Brown, Elizabeth R.
A1 Mohamed Bakhash, Shah A.
A1 Baker, Noah R.
A1 Castor, Jared
A1 Livingston, Robert J.
A1 Huang, Meei-Li
A1 Jerome, Keith R.
A1 Greninger, Alexander L.
A1 Roychoudhury, Pavitra
YR 2021
UL http://medrxiv.org/content/early/2021/05/25/2021.05.23.21257679.abstract
AB Across 20 vaccine breakthrough cases detected at our institution, all 20 (100%) infections were due to variants of concern (VOC) and had a median Ct of 20.2 (IQR=17.1-23.3). When compared to 5174 contemporaneous samples sequenced in our laboratory, VOC were significantly enriched among breakthrough infections (p < .05).Competing Interest StatementA.L.G. reports contract testing from Abbott Laboratories and research support from Gilead and Merck, outside of the described work.Funding StatementThis work is supported by the National Institutes of Health [ORIP grant S10OD028685 to Scientific Computing at Fred Hutch, and UW-Fred Hutch CFAR AI027757 to P.R.].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the University of Washington Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequences have been deposited to GISAID.